James Hilger

713 total citations
40 papers, 501 citations indexed

About

James Hilger is a scholar working on Genetics, Hematology and Pathology and Forensic Medicine. According to data from OpenAlex, James Hilger has authored 40 papers receiving a total of 501 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Genetics, 18 papers in Hematology and 14 papers in Pathology and Forensic Medicine. Recurrent topics in James Hilger's work include Chronic Lymphocytic Leukemia Research (22 papers), Lymphoma Diagnosis and Treatment (13 papers) and Multiple Myeloma Research and Treatments (11 papers). James Hilger is often cited by papers focused on Chronic Lymphocytic Leukemia Research (22 papers), Lymphoma Diagnosis and Treatment (13 papers) and Multiple Myeloma Research and Treatments (11 papers). James Hilger collaborates with scholars based in United States, Australia and China. James Hilger's co-authors include Constantine S. Tam, Jane Huang, Youram Nassir, Stephen Opat, James R. Berenson, Regina A. Swift, Robert Vescio, Ori Yellin, David Simpson and Ralph V. Boccia and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Vision Research.

In The Last Decade

James Hilger

38 papers receiving 495 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
James Hilger United States 13 272 231 214 163 161 40 501
Peter Holman United States 14 72 0.3× 96 0.4× 170 0.8× 95 0.6× 234 1.5× 72 541
Aditi Shastri United States 12 130 0.5× 18 0.1× 317 1.5× 173 1.1× 104 0.6× 59 546
Laura Vanelli Italy 13 528 1.9× 91 0.4× 512 2.4× 309 1.9× 86 0.5× 35 848
Simona Martin Germany 8 92 0.3× 107 0.5× 140 0.7× 72 0.4× 130 0.8× 12 327
U Schmücker Germany 6 191 0.7× 130 0.6× 48 0.2× 139 0.9× 89 0.6× 10 401
Mary Gleeson United Kingdom 10 83 0.3× 186 0.8× 183 0.9× 341 2.1× 188 1.2× 31 651
B Kaiser-McCaw United States 8 91 0.3× 66 0.3× 140 0.7× 91 0.6× 54 0.3× 17 312
Kazuki Taoka Japan 10 127 0.5× 73 0.3× 150 0.7× 206 1.3× 86 0.5× 34 431
Jianling Ji United States 10 62 0.2× 42 0.2× 54 0.3× 126 0.8× 61 0.4× 39 378
Dorota Jeziorowska France 9 87 0.3× 87 0.4× 67 0.3× 205 1.3× 83 0.5× 10 404

Countries citing papers authored by James Hilger

Since Specialization
Citations

This map shows the geographic impact of James Hilger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Hilger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Hilger more than expected).

Fields of papers citing papers by James Hilger

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James Hilger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Hilger. The network helps show where James Hilger may publish in the future.

Co-authorship network of co-authors of James Hilger

This figure shows the co-authorship network connecting the top 25 collaborators of James Hilger. A scholar is included among the top collaborators of James Hilger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James Hilger. James Hilger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cheah, Chan Y., Constantine S. Tam, Masa Lasica, et al.. (2022). A Phase 1 Study with the Novel B-Cell Lymphoma 2 (Bcl-2) Inhibitor Bgb-11417 As Monotherapy or in Combination with Zanubrutinib (ZANU) in Patients (Pts) with CLL/SLL: Preliminary Data. Blood. 140(Supplement 1). 2321–2323. 11 indexed citations
2.
Trotman, Judith, Stephen Opat, David Gottlieb, et al.. (2020). Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up. Blood. 136(18). 2027–2037. 73 indexed citations
3.
Hillmen, Peter, Jennifer R. Brown, Barbara Eichhorst, et al.. (2020). ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. Future Oncology. 16(10). 517–523. 56 indexed citations
4.
Hillmen, Peter, Jennifer R. Brown, John C. Byrd, et al.. (2019). Alpine: Phase 3 Trial of Zanubrutinib (BGB-3111) Vs Ibrutinib in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). Blood. 134(Supplement_1). 4307–4307. 2 indexed citations
5.
Othman, Jad, Emma Verner, Constantine S. Tam, et al.. (2018). Severe hemolysis and transfusion reactions after treatment with BGB-3111 and PD-1 antibody for Waldenström macroglobulinemia. Haematologica. 103(5). e223–e225. 7 indexed citations
6.
Cull, Gavin, Stephen Opat, Judith Trotman, et al.. (2017). Safety and Activity of the Highly Specific BTK Inhibitor BGB-3111 in Combination with the PD-1 Inhibitor BGB-A317 in Patients with B-Cell Lymphoid Malignancies. Blood. 130. 4057–4057. 2 indexed citations
7.
8.
Trotman, Judith, Stephen Opat, Paula Marlton, et al.. (2017). BRUTON'S TYROSINE KINASE (BTK) INHIBITOR BGB‐3111 DEMONSTRATES HIGH VERY GOOD PARTIAL RESPONSE (VGPR) RATE IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA (WM). Hematological Oncology. 35(S2). 70–71. 15 indexed citations
9.
Seymour, John F., Stephen Opat, Gavin Cull, et al.. (2017). HIGH OVERALL RESPONSE RATE WITH THE BTK INHIBITOR BGB‐3111 IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA: AN UPDATE ON SAFETY AND ACTIVITY. Hematological Oncology. 35(S2). 234–235. 5 indexed citations
10.
11.
12.
Berenson, James R., James Hilger, Ori Yellin, et al.. (2014). Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy. Leukemia. 28(7). 1529–1536. 55 indexed citations
13.
Berenson, James R., James Hilger, Ori Yellin, et al.. (2013). A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma. Annals of Hematology. 93(1). 89–98. 34 indexed citations
14.
Hilger, James, James R. Berenson, Leonard M. Klein, et al.. (2013). A phase I/II study (NCT01541332) of pomalidomide (POM), dexamethasone (DEX), and pegylated liposomal doxorubicin (PLD) for patients with relapsed/refractory (R/R) multiple myeloma (MM).. Journal of Clinical Oncology. 31(15_suppl). 8598–8598. 3 indexed citations
15.
Berenson, James R., Ori Yellin, Robert Dichmann, et al.. (2012). A phase I/II study of carfilzomib (CFZ) as a replacement for bortezomib (BTZ) for multiple myeloma (MM) patients (Pts) progressing while receiving a BTZ-containing combination regimen.. Journal of Clinical Oncology. 30(15_suppl). 8098–8098. 5 indexed citations
16.
Berenson, James R., Ori Yellin, Ravi Patel, et al.. (2011). A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma patients. British Journal of Haematology. 155(5). 580–587. 25 indexed citations
17.
Berenson, James R., Ori Yellin, John Crowley, et al.. (2010). Prognostic factors and jaw and renal complications among multiple myeloma patients treated with zoledronic acid. American Journal of Hematology. 86(1). 25–30. 15 indexed citations
18.
Kalar, Donald, Patrick Garrigan, Thomas D. Wickens, James Hilger, & Philip J. Kellman. (2009). A unified model of illusory and occluded contour interpolation. Vision Research. 50(3). 284–299. 22 indexed citations
19.
Fantoni, Carlo, James Hilger, Walter Gerbino, & Philip J. Kellman. (2008). Surface interpolation and 3D relatability. Journal of Vision. 8(7). 29–29. 15 indexed citations
20.
Natale, Ronald B., Marti McKinley, James Hilger, & T.G. Myers. (2007). Phase I/II trial of bortezimib and pemetrexed in patients with advanced non-small cell lung cancer. Journal of Clinical Oncology. 25(18_suppl). 18145–18145. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Peter Holman Breakdown of academic impact, for papers by Aditi Shastri Breakdown of academic impact, for papers by Laura Vanelli Breakdown of academic impact, for papers by Simona Martin Breakdown of academic impact, for papers by U Schmücker Breakdown of academic impact, for papers by Mary Gleeson Breakdown of academic impact, for papers by B Kaiser-McCaw Breakdown of academic impact, for papers by Kazuki Taoka Breakdown of academic impact, for papers by Jianling Ji Breakdown of academic impact, for papers by Dorota Jeziorowska
Rankless by CCL
2026